Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Company Description and Summary of Significant Accounting Policies [Abstract]
Transfers in into Level 3	$ 0	$ 0
Transfers out of Level 3	0	0
Recurring Basis [Member]
Assets [Abstract]
Assets at fair value	49	219
Recurring Basis [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	49	219
Recurring Basis [Member] \| Level 1 [Member]
Assets [Abstract]
Assets at fair value	49	219
Recurring Basis [Member] \| Level 1 [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	49	219
Recurring Basis [Member] \| Level 2 [Member]
Assets [Abstract]
Assets at fair value	0	0
Recurring Basis [Member] \| Level 2 [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	0	0
Recurring Basis [Member] \| Level 3 [Member]
Assets [Abstract]
Assets at fair value	0	0
Recurring Basis [Member] \| Level 3 [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	$ 0	$ 0